Immunotherapy in metastatic prostate cancer

Area of Science:

• Oncology
• Immunology
• Cancer Therapeutics

Background:

• Immunotherapy has transformed cancer treatment, yet its application in prostate cancer (PCa) remains restricted.
• Sipuleucel-T is the sole immunotherapy agent currently approved for PCa management.

Purpose of the Study:

• To review the current status and future potential of various immunotherapeutic strategies in prostate cancer treatment.
• To evaluate the efficacy and challenges associated with immune checkpoint inhibitors (ICIs), T-cell engagers (TCEs), and chimeric antigen receptor (CAR)-T cells in PCa.

Main Methods:

• Review of Phase II/III trial data for ICIs in monotherapy and combination settings.
• Analysis of early-phase clinical data for TCEs, focusing on efficacy and toxicity.
• Assessment of feasibility and safety data from early-phase clinical trials of CAR-T cells in PCa.

Main Results:

• Phase II/III trials of ICIs have not yet yielded positive results in prostate cancer.
• Early data for TCEs are encouraging, but clinical adoption is hindered by anti-drug antibodies and toxicities.
• CAR-T cells have shown feasibility and acceptable safety in initial trials, with ongoing development aiming to improve outcomes.

Conclusions:

• Current immunotherapy options for prostate cancer are limited, with mixed results for ICIs.
• TCEs and CAR-T cells present promising avenues, but further research is needed to overcome existing challenges and enhance therapeutic effectiveness.